Breaking News on Global Pharmaceutical Technology & Manufacturing

Headlines > April 2014

« Previous month Next month »

Aesica to lead £200,000 project to improve manufacturing of API

30-Apr-2014 - Aesica has secured a Technology Strategy Board grant to fund a high-value chemical manufacturing process with the winning process set to improve the sustainability of an active pharmaceutical Ingredient (API).

News in brief

Indian state regulator revokes manufacturing suspension at Wockhardt plant

30-Apr-2014 - A Wockhardt facility sanctioned by Indian authorities last week has resumed production of three fixed dose combination (FDC) drugs.

EMA issues guidance to ensure job transparency for departing staff

30-Apr-2014 - The European Medicines Agency (EMA) has published guidance for departing employees intended to ensure there is no conflict of interest in their new roles.

Colorcon expands Indian excipients site to capture generics market

30-Apr-2014 - Colorcon today opened an expanded facility in Goa, India to scale up production of tablet coatings and excipients for pharmaceutical manufacturers in South Asia.

Emerging excipient markets to outpace Western markets, report says

30-Apr-2014 - Experts have predicted emerging Indian and Chinese markets will outpace Western markets as the $2.3bn oral solid dosage form (OSDF) excipients global market grows at a sustainable rate.

'No longer simply a capsule provider' - Capsugel wins oral peptide contract

29-Apr-2014 - Capsugel is no longer a simple capsule provider but a differentiated player in the CDMO industry, the firm says as it wins a scale-up manufacturing contract for Chiasma and Roche’s...

Swiss gold delivers hope as carrier for cancer drugs

29-Apr-2014 - Researchers in Switzerland have devised a form of gold nanoparticle that shows promise as a weapon against tumours and as a delivery vehicle for drugs.

API facility issues cause FDA to reject Pozen drug candidates

29-Apr-2014 - Deficiencies of at an unnamed API supplier caused the US FDA to reject Pozen’s aspirin-based drug candidates with a complete response letter (CRL).

Endo acquires migraine treatment, needle-free delivery system for $85M

28-Apr-2014 - Endo Pharmaceuticals, which previously lost a bid to acquire a migraine treatment, has now acquired worldwide rights to Sumavel DosePro (sumatriptan injection) for subcutaneous use, which is a needle-free delivery system for...

People on the Move

US FDA director who led Ranbaxy compliance action moves to Mylan

28-Apr-2014 - This week's People on the Move column features new appointments in the US Food and Drug Administration, Mylan, Biocon and elsewhere.

AZ refuses $100bn bid, but Pfizer ‘confident’ of ‘compelling’ offer

28-Apr-2014 - AstraZeneca says Pfizer has “very significantly undervalued” the company after confirming rumours it had received an offer worth £59bn ($100bn).

Industry seeks to expand investments in manufacturing, report finds

28-Apr-2014 - As pharma manufacturers look to cut costs and increase quality, over 70% of industry executives interviewed for a recent CPhI report say they are actively investing in manufacturing techniques and...

News in brief

Strides Arcolab wins FDA approval for India facility

28-Apr-2014 - Strides Arcolab announced Friday that its oral dosage manufacturing site in Bangalore, India, was recently approved by the US FDA following a GMP compliance audit. 

Indian state regulator suspends manufacture of drug at Wockhardt plant

24-Apr-2014 - Indian authorities have suspended the manufacture of a Wockhardt fixed dose combination drug, the company has announced in a filing.

Opko acquires Israeli-made dry powder inhaler to treat respiratory disorders

24-Apr-2014 - Opko Health has agreed to acquire Inspiro Medical, an Israeli medical device company developing a new platform to deliver small molecule drugs such as corticosteroids and beta agonists or larger molecules...

Frutarom becomes a bigger botanicals player with THMPD range

23-Apr-2014 - Swiss-Israeli supplier Frutarom has beefed up its botanical extracts in response to changing European Union laws for herbal products and medicines.

Novartis scoops GSK’s oncology portfolio, trades away its vaccine division

23-Apr-2014 - Novartis has agreed to acquire GlaxoSmithKline’s oncology pipeline for as much as $16bn, while GSK will acquire Novartis’ vaccine business, excluding the flu vaccines, for as much as $7bn.

UK generics makers and MHRA pool manufacturing knowledge

23-Apr-2014 - The British Generic Manufacturers Association (BGMA) and the UK Medicines and Healthcare Products Regulatory Agency (MHRA) will launch a forum for the generics industry to discuss manufacturing and quality issues.

Merck & Co. contracts Catalent to make sublingual hayfever drugs

23-Apr-2014 - MSD has selected Catalent to manufacture two recently approved sublingual pollen extract drugs using its Zydis formulation platform.


AZ for $100bn? Pfizer could buy Azerbaijan and keep the change

22-Apr-2014 - With Pfizer rumoured to be on the brink of a mega-merger with AstraZeneca, brings you an interactive view of what £60bn ($101bn) could get.

Big Pharma pull out and share slump won’t silence RNAi advocates

22-Apr-2014 - RNA interference (RNAi) developers that saw stock prices fall after Novartis pulled out of the market last week have reiterated their belief in the therapeutic and revenue potential of gene...

Hospira announces two US recalls due to manufacturing, supplier issues

22-Apr-2014 - Hospira has announced US recalls for seven lots of its propofol injection and one lot of 1% Lidocaine HCI Injection due to a glass contamination.

US to lose 140,000 jobs if status quo is maintained, PhRMA reports

18-Apr-2014 - Biopharma executives believe there will be strong growth in domestic R&D activities and biopharma manufacturing, but fewer workers will be needed as efficiencies in productivity are achieved across the industry,...

Albemarle to sell ibuprofen business to SI Group

17-Apr-2014 - Albemarle has agreed to sell its ibuprofen business to US chemical intermediates firm SI Group in a deal that will also see it divest the anaesthetic agent, propofol.

Swiss site for API maker Cerbios combines chemical and biological R&D

17-Apr-2014 - Swiss high potency active pharmaceutical ingredient (API) contractor Cerbios has broken ground on a building that will bring together its chemical and biological R&D departments.

« Previous month Next month »

Key Industry Events


Access all events listing

Our events, Shows & Conferences...